Clinical Studies

Silenseed completed a Phase 1/2a clinical study for its first target - pancreatic cancer. The study was conducted in 15 patients with Locally Advanced Pancreatic Cancer (LAPC). The conclusions from this study suggest that "a combination of siG12D LODER and chemotherapy is well tolerated. The combination has demonstrated promising efficacy in locally advanced pancreatic cancer with durable responses" Read more

Phase II Clinical Trial for Pancreatic Cancer - Currently Recruiting

Silenseed is to begin a Phase II multicenter trial for its pancreatic cancer treatment. The study, which has been approved by the US Food and Drug Administration (FDA), will be held at several leading medical centers in the US with the participation of 80 patientsRead More

siG12D LODER Reaches Undrugable Targets

The Silenseed siG12D-LODER enables the targeting of the dominant oncogene KRAS, which so far is considered as ‘undruggable’. siG12D-LODER is a miniature biodegradable polymeric matrix that encompasses an anti KRASG12D siRNA drug, designed to release the drug regionally within a pancreatic tumor at a prolonged rate for a period of ~12-16 weeks. Read More